COMMUNIQUÉS West-GlobeNewswire
-
Lexicon Pharmaceuticals to Host 2024 Investor Day
18/04/2024 - 14:00 -
Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results
18/04/2024 - 14:30 -
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
18/04/2024 - 14:30 -
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
18/04/2024 - 14:30 -
Korro Announces $70 Million Private Placement
18/04/2024 - 14:30 -
Ultimovacs ASA – Annual General Meeting held on April 18, 2024
18/04/2024 - 14:42 -
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
18/04/2024 - 14:45 -
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
18/04/2024 - 15:00 -
Digital Utilities Ventures Completes Strategic Merger - Paving the Way for Future Growth and Innovation
18/04/2024 - 15:00 -
Precision Optics Announces Receipt of $720,000 Follow-On Production Order from Top Tier Defense/Aerospace Customer for New Optical Application
18/04/2024 - 15:00 -
Hapbee Announces Closing of Private Placement
18/04/2024 - 15:00 -
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
18/04/2024 - 15:00 -
Pharming Group announces the placement of €100 million convertible bonds due 2029
18/04/2024 - 15:04 -
Sanara MedTech Inc. Announces $55 Million Debt Facility
18/04/2024 - 15:15 -
RadNet’s Delaware Imaging Network Announces Ribbon-Cutting Ceremony for Mammography Service at Milford Walmart
18/04/2024 - 15:18 -
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
18/04/2024 - 15:25 -
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
18/04/2024 - 15:30 -
Immix Biopharma on Track to Dose NXC-201 Patients in United States
18/04/2024 - 15:32 -
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States
18/04/2024 - 15:37
Pages